Choosing between Stereotactic and Hypofractionated Radiotherapy for inoperable Stage I NSCLC, summarised by Gustavo Viani
Gustavo Viani, Associate Professor, Faculdade de Medicina de Ribeirão Preto (FMRP) da USP, shared a post on LinkedIn:
“SBRT resulted in acceptable tumor control compared with CRT with limited toxic effects in lung cancer‼️
-Design
– Phase 3 RCT comparing SBRT and CRT for medically inoperable stage I NSCLC
– 233 randomized 2:1 to SBRT (154) or CRT (79)
– SBRT doses: 48 Gy (4 fractions) for peripheral NSCLC and 60 Gy (8 fractions) for central NSCLC
– CRT dose: 60 Gy (15 fractions).
Results:
-3-year local control 87.6% SBRT vs. 81.2% fCRT (HR, 0.61; P = .15)
– Minimal acute toxic effects; grade 5 hemoptysis occurred in 1 SBRT patient
Conclusion:
SBRT showed slightly local control, but No significant survival benefit.”
Authors: Anand Swaminath, et al.
Source: Gustavo Viani/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023